FinnGen is one of the very first personalized medicine projects at this scale and brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks and international pharmaceutical companies and hundreds of thousands of Finns.
The FinnGen study will construct a unique resource of 500 000 Finns that enables ambitious study designs to improve our understanding of the genetic background of diseases and subsequently for implementation of genome medicine in clinical practice and drug development. FinnGen aims on one hand to provide useful and exciting new data but also construct a world-class resource that can be applied for future studies that combine genetic and health data in a way that is currently not possible on this scale.
The FinnGen project is an academic-pharma partnership that involves nine Finnish biobanks, and FINBB, all Finnish University Hospitals and their respective Universities, the Institute of Health and Welfare (THL), the Finnish Red Cross Blood Service and 13 partners (Abbvie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Merck/MSD, Pfizer and Sanofi, Janssen, Novartis, Maze Therapeutics and Boehringer Ingelheim) to develop the potential of these resources to serve medicine.
According to the FinnGen consortium agreement, FinnGen results are subjected to one year embargo and, after that, can be made available to the larger scientific community. Data releases are done twice a year. The results can be browsed with the web browser and summary statistics data can be downloaded from Google cloud storage free of charge.
Note that you can access biobank results through FINGENIOUS, one-stop digital gateway to Finnish Biobanks and Biomedical Research.
Health & Wellbeing, Invest in Finland